MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma.

ABSTRACT:

Introduction

Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system and accounts for more than 90 % of all renal tumors. Resistance to targeted therapy has emerged as a pivotal factor that contributes to the progressive deterioration of patients with advanced RCC. Metabolic reprogramming is a hallmark of tumorigenesis and progression, with an increasing body of evidence indicating that abnormal lipid metabolism plays a crucial role in the advancement of renal clear cell carcinoma.

Objectives

Clarify the precise mechanisms underlying abnormal lipid metabolism and drug resistance.

Methods

Bioinformatics screening and analyses were performed to identify hub gene. qRT-PCR, western blot, chromatin immunoprecipitation (ChIP) assays, and

SUBMITTER: Wei Z 

PROVIDER: S-EPMC11976417 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature